secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genvor Inc (GNVR)
CIK:        0001792941
Form:       8-K
Filed at:   2026-05-21T20:15:19+00:00
Accession:  0001903596-26-000235
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genvor appoints Donald Kalkofen CFO; $14K monthly cash + 575K options, going-concern clause in deferred pay
--------------------------------------------------------------------------------

- Donald Kalkofen appointed CFO effective May 18, 2026; 20+ years biotech/tech CFO experience including IPO at Alpha Cognition.
- Cash compensation $6,250/month plus deferred $7,750/month; total $14,000/month from Jan 2027.
- Options for 575,000 shares: 425,000 vest monthly over 12 months, 150,000 vest upon successful exchange listing.
- Deferred comp due by Dec 31, 2026, but can be delayed if board determines going-concern risk.
- Options forfeited if shareholder approval of equity plan not obtained by next annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792941/000190359626000235/0001903596-26-000235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792941/000190359626000235/gnvr_8k.htm
  HTML page:      https://secwatch.observer/filing/0001903596-26-000235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer